How about the R&D pipeline of small biomolecules with a loss of 700 million yuan per year without loss of capital favor and reputation?

Text | Ye Fenghong

Some time ago, Shanghai Heyu Bio-Pharmaceutical Technology Co.

Annual loss of 700 million, high R&D investment

As a biopharmaceutical company in early clinical development, since its establishment in 2016, Heyu Biotech has been very focused on the development of small-molecule tumor-targeted drugs, small-molecule tumor immune drugs and their combination therapies.

At present, Heyu Biological does not have commercial products, and does not get any income from product sales

Core pipeline analysis

1.

ABSK011 is a highly effective and selective FGFR4 (fibroblast growth factor receptor 4) inhibitor.

At present, there are no FGFR4 selective inhibitors on the market in the world, and there are about 8 drug candidates in different stages of clinical development, including ABSK011

As one of the deadliest cancers in the world, the number of new cases of hepatocellular carcinoma in China will reach 378,600 in 2020, and it is expected to reach 473,400 by 2030.

2.

ABSK091, formerly known as AZD4547, is a highly effective and selective inhibitor of FGFR subtypes 1, 2 and 3

According to Frost & Sullivan data, FGFR mutations and abnormal activation are related to the development of a variety of cancers.

3.

ABSK021 is an effective small molecule CSF-1R inhibitor with good oral bioavailability and selectivity.

ABSK021 has initiated phase Ib clinical trials in the United States and China to evaluate the safety, tolerability, PK characteristics and anti-tumor efficacy of ABSK021

4.

CXCR4 (chemokine receptor 4) belongs to the G protein-coupled receptor superfamily, and has biological functions such as chemotaxis of immune cells and maintaining the dynamic balance of immune cells

5.

ABSK043 is a small molecule PD-L1 inhibitor with good oral bioavailability and high selectivity.
It is being developed for the treatment of various cancers and potential non-oncology indications
.
Although anti-PD-1/anti-PD-L1 antibodies have revolutionized cancer treatment, antibody-based immunotherapy has many shortcomings, such as high cost, lack of oral bioavailability and immunogenicity, and these defects may be suppressed by small molecules Agent to be improved
.
ABSK043 specifically binds to PD-L1, which may cause PD-L1 dimerization and cell surface internalization
.
Pre-clinical data has proved that ABSK043 can strongly inhibit the interaction of PD-1/PD-L1 and can rescue the inhibition of PD-L1 mediated T cell activation
.
ABSK043 also shows strong anti-tumor efficacy and excellent safety in multiple preclinical models
.

6.
ABSK071 (KRAS)

ABSK071 is a potent, good oral bioavailability, irreversible small molecule variant form of KRAS inhibitor, with strong potency in biochemical and cellular environments
.
ABSK071 showed strong in vitro activity against KRAS mutations in cell proliferation and targeted regulation analysis
.
It also shows good ADME and physical and chemical properties
.

7.
ABSK051 (CD73)

ABSK051 is a small molecule CD73 inhibitor
.
ABSK051 has shown strong efficacy in inhibiting soluble and surface-expressed CD73 activity
.
It also shows strong in vivo efficacy in a variety of animal models
.

ABSK051 has been marked as a preclinical drug candidate
.
We are currently conducting research on ABSK051's IND activation
.

(The original text has been deleted)

Reference source:

acobson, O.
and ID Weiss, CXCR4 chemokine receptor overview: biology, pathology and applications in imaging and therapy.
Theranostics, 2013.
3(1): p.
1-2.

https://www1.
hkexnews.
hk/app/sehk/2021/103566/documents/sehk21061601467_e.
pdf.